Featured Stories
Japanese OK In COPD Gives AstraZeneca’s Breztri Aerosphere First Regulatory Approval
AstraZeneca’s respiratory chief tells Scrip Japan’s approval of the triple-combination inhaled therapy is both a milestone for treating COPD and for the UK pharma’s strategy.
Sanofi’s Ameet Nathwani Brings Life Sciences R&D Expertise To The Digital Space
Nathwani talks to Scrip about his unique dual role as chief medical officer and chief digital officer, Sanofi’s approach to digital therapeutics, and major hurdles to turning the promise of such technologies into a reality for patients.
No-Deal Brexit 'Very Bad' For Business And Patients
Peter Martin, COO of Norgine, is concerned about the ‘mood music’ in the political environment in the UK, and warns about the risks of the UK leaving the EU without a deal in place.
Latest News
Recent Tweets from ScripPRECISION MEDICINE RESEARCH: How Advanced Data Analytics Support The Journey From Clinic to Bedside
Precision medicine offers huge promise to patients and health systems. It can also substantially increase the efficiency of drug development by enabling more focused, data-rich clinical trials.
Embedding Time-Critical Scheduling in Drug Production
Manufacturing is the engine room of the pharmaceutical industry. Ultimately, a medicine has little value if it does not reach patients on schedule, in the required quantity and quality. Download this whitepaper which discusses time-critical scheduling in drug production.
Commercial Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Amphastar Poised To Receive $59.9m In Momenta/Sandoz Settlement
The small generic drug company has talked about using the cash windfall from the expected settlement to fund clinical trials and possibly M&A.
Finance Watch: Polaris Piles On As Multiple Life Science VCs Raise New Funds
Private Company Edition: Polaris is raising up to $400m for its next tech and health care fund, following in the footsteps of several life science investors this year. Also, Nevakar raises $50m in a product financing agreement and RAPT closes a $37m series C extension.
AstraZeneca Plans $630m Korea Investment Amid Favorable Policies
AstraZeneca plans hefty investment in South Korea’s biomedical sector over next few years, in a signal of multinationals' improved sentiment over the government’s recently announced plans to nurture the bio-health industry as a major growth engine.
Roche Beats Rivals To Japan Tumor-Agnostic Market With World-First Rozlytrek Nod
Roche’s tumor-agnostic drug receives first approval globally in Japan following an expedited review, giving the Swiss group a lead over its rival in this market. But sales may be limited.
Asia Deal Watch: BeiGene And Celgene Exit Their Anti-PD-1 Collaboration
The Chinese firm regains all rights to tislelizumab ahead of the closing of Celgene’s merger with Bristol-Myers Squibb. BeiGene also forms cancer JV with US biotech SpringWorks.
Cash Injection Fuels Viela Bio's NMOSD FDA Filing
New and existing investors in Viela Bio have raised $75m in the latest funding round, allowing the AstraZeneca spin off to progress its NMOSD antibody to regulatory filing in the US. However, established companies may have stolen a march on commercializing a treatment.
Sanofi/Google Alliance To Apply Big Data To R&D, Commercial And Marketing Operations
Sanofi says the virtual innovation lab it will create with Google will enable precision health care and optimize R&D and commercial operations. Incoming CEO Hudson has been tasked with improving the pharma’s R&D and digital capabilities.
Array's Three Value Drivers Align With Pfizer's Three Oncology Pillars In $11.4bn Deal
Pfizer is buying Array for a 62% premium, citing its Braftovi/Mektovi drug combo, pipeline of targeted cancer therapies and royalty revenue from partnered assets as key value drivers, aligning with the three pillars the big pharma recently outlined for its oncology strategy.
Policy & Regulation Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
US FDA Approval Of Novo Nordisk's Victoza For Young T2D Patients A Treatment Milestone
The new indication means Victoza is the first non-insulin drug approved to treat type 2 diabetes in young patients since metformin was approved for pediatric use in 2000. Victoza has been approved to treat adult patients with type 2 diabetes since 2010.
Korea Steps Up AI Adoption In Drug Discovery, Repositioning And Surveillance
South Korea is stepping up the adoption of artificial intelligence to speed up drug development by selecting discovery, repositioning and smart drug surveillance as three initial focus areas for new AI/big data platforms.
USAID Reviewing India Financing Effort With Troubled DHFL
The US Agency for International Development (USAID) is monitoring its Indian healthcare financing initiative with Dewan Housing Finance Corporation amid simmering concerns over the liquidity position of the mortgage lender.
How Can Korea Grab Window Of Opportunity In AI Drug Development?
Participants at a recent policy forum in Seoul stressed the need to secure appropriate technology and expertise, unify government support and draw up a joint cooperation plan between industry and government as key factors in advancing AI-guided new drug development in South Korea.
Research & Development Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Tremfya And Taltz Provide PsA Highlights At EULAR
The spotlight was on anti-interleukin drugs at the Madrid meeting last week, especially their role in advancing the treatment of psoriatic arthritis.
Dosing Woes For VBI Vaccines As Share Price Plummets On Hep B Study Results
Despite positive results in the latest Phase III PROTECT study of its hepatitis B vaccine, VBI Vaccines failed to show non-inferiority at two doses, leaving it trailing behind competitor Dynavax and its established two-dose product.
Q&A: SVP Elliott Levy On Amgen R&D's 'Singular Focus On Innovation'
Scrip spoke with Levy, senior vice president of global development, about the company's novel candidates for cardiovascular and inflammatory diseases and cancer, including modalities outside of its primary focus on biologics and small molecules.
Pipeline Watch: A Phase III Start In Celiac Disease
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.